Search
Zevra Therapeutics Inc
ZVRAAdd to Watchlist
13.980USD
+0.170+1.23%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
826.43MMarket Cap
6.63P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.23%
5 Days
+5.67%
1 Month
+28.49%
6 Months
+67.63%
Year to Date
+56.03%
1 Year
+48.57%
Key Figures
13.850Open
14.040High
1.42MVolume
6.63P/E TTM
14.39P/E Dynamic
--Dividend TTM
2.41%Turnover Ratio
13.810Prev. Close
13.525Low
13.50MTurnover
LossP/E Static
4.02P/B
0.00%Div Yield TTM
55.05%ROA
13.16052wk High
1.61Volume Ratio
-105.51MNet Profit
59.11MShares
2.1087EPS TTM
0.91Beta
96.08%ROE
7.16052wk Low
3.73%Amplitude
213.48%Gross Margin
826.43MMarket Cap
7.79Reward/Risk
3.34%Risk Rate
TradingKey Stock Score of Zevra Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Zevra Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 48 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 28.25.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Zevra Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Zevra Therapeutics Inc Highlights
StrengthsRisks
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 287.71% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 6.63, at a high 3-year percentile range.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 841.10K shares of this stock.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
28.250
Target Price
+101.64%
Upside Space
Zevra Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Zevra Therapeutics Inc Info
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
Ticker SymbolZVRA
CompanyZevra Therapeutics Inc
CEOMcfarlane (Neil F)
Websitehttps://zevra.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
53029.200
+186.700 (+0.35%)
29550.600
+239.200 (+0.82%)
7505.200
+33.700 (+0.45%)
15055.000
+252.000 (+1.70%)
69454.000
+1306.000 (+1.92%)
6380.800
+28.000 (+0.44%)
68.953
+0.609 (+0.89%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4177.340
+55.430 (+1.34%)
FAQs
What is the current price of Zevra Therapeutics Inc (ZVRA)?
The current price of Zevra Therapeutics Inc (ZVRA) is 13.98.
What is the symbol of Zevra Therapeutics Inc?
The ticker symbol of Zevra Therapeutics Inc is ZVRA.
What is the 52-week high of Zevra Therapeutics Inc?
The 52-week high of Zevra Therapeutics Inc is 13.16.
What is the 52-week low of Zevra Therapeutics Inc?
The 52-week low of Zevra Therapeutics Inc is 7.16.
What is the market capitalization of Zevra Therapeutics Inc?
The market capitalization of Zevra Therapeutics Inc is 826.43M.
Is Zevra Therapeutics Inc (ZVRA) currently rated as Buy, Hold, or Sell?
According to analysts, Zevra Therapeutics Inc (ZVRA) has an overall rating of Buy, with a price target of 28.25.
What is the Earnings Per Share (EPS TTM) of Zevra Therapeutics Inc (ZVRA)?
The Earnings Per Share (EPS TTM) of Zevra Therapeutics Inc (ZVRA) is 1.40.